Intrahepatic cholangiocarcinoma

Intrahepatic cholangiocarcinoma is a bile-duct cancer that starts inside the liver. This entry covers mass-forming tumours, FGFR2 and IDH1, and resection.

Overview

Intrahepatic cholangiocarcinoma (iCCA) is a primary malignant neoplasm arising from the epithelial cells of the bile ducts located proximal to the second-order bile ducts (i.e., within the liver parenchyma). It is the second most common primary liver cancer after hepatocellular carcinoma (HCC), accounting for approximately 10–20% of all primary hepatic malignancies and 10–15% of all cholangiocarcinomas (the remainder being perihilar and distal extrahepatic).

Unlike HCC, which typically arises in the setting of cirrhosis, iCCA frequently develops in non-cirrhotic livers, though chronic inflammation and biliary tract disease are significant risk factors. It is characterized by a desmoplastic stromal reaction, early perineural and lymphatic invasion, and a propensity for intrahepatic metastasis via vascular invasion. The prognosis remains guarded, largely due to late diagnosis and limited efficacy of systemic therapies in advanced stages.

Epidemiology and Global Burden

The incidence of iCCA has been rising globally over the past three decades, while extrahepatic cholangiocarcinoma rates have remained stable or declined. This increase is partially attributed to improved diagnostic imaging and pathological classification (distinguishing iCCA from metastatic adenocarcinoma or HCC), but a true rise in incidence—potentially linked to metabolic syndrome and non-alcoholic fatty liver disease (NAFLD)—is strongly suspected.

Epidemiological Feature	Details
Global Incidence	0.3 – 3.5 per 100,000 person-years (varies significantly by region).
High-Risk Regions	Northeast Thailand (Khon Kaen), China, Korea, Japan (associated with liver fluke infection).
Western Countries	Rising incidence (approx. 1–2 per 100,000); male predominance (M:F ≈ 1.2–1.5:1).
Median Age at Diagnosis	65–75 years (sporadic cases); younger in fluke-endemic areas.
Mortality	High; 5-year overall survival < 10% for all stages combined.
Trend	Annual percentage change (APC) increasing ~3–5% per year in US/Europe.

Etiology and Risk Factors

While the majority of iCCA cases are sporadic (no identifiable risk factor), several conditions confer a significantly elevated risk. The common pathophysiological denominator is chronic biliary inflammation and epithelial injury leading to dysplasia and malignant transformation.

Established Risk Factors

Risk Factor Category	Specific Conditions	Relative Risk / Mechanism
Parasitic Infection	Opisthorchis viverrini, Clonorchis sinensis (Liver Flukes)	Highest RR (5–50x). Chronic mechanical irritation, nitrosamine production, inflammatory cytokine release (IL-6, TNF-α). Endemic in SE Asia.
Primary Sclerosing Cholangitis (PSC)	IBD-associated (Ulcerative Colitis > Crohn’s)	RR 100–300x. Lifetime risk 5–10%. Often occurs in younger patients (30s–40s). Difficult surveillance due to dominant strictures.
Congenital/Structural	Caroli Disease, Choledochal Cysts (Todani Type I, IV), Biliary Papillomatosis	Chronic stasis, stone formation, reflux of pancreatic enzymes. Risk persists even post-resection of cyst (remnant duct epithelium).
Hepatobiliary Stones	Hepatolithiasis (Recurrent Pyogenic Cholangitis)	Common in East Asia. Stones cause chronic inflammation, strictures, and epithelial hyperplasia.
Viral Hepatitis	Chronic Hepatitis B (HBV), Hepatitis C (HCV)	RR 2–5x. Independent of cirrhosis. HCV stronger association than HBV. Mechanisms: direct viral oncogenesis, chronic inflammation, oxidative stress.
Cirrhosis (All Etiologies)	Alcohol, NAFLD/NASH, Hemochromatosis, PBC	Architectural distortion, regenerative nodules, chronic inflammation. iCCA in cirrhosis often mimics HCC on imaging.
Metabolic Syndrome	Obesity, Type 2 Diabetes Mellitus (T2DM), NAFLD/NASH	Emerging major driver in West. Insulin resistance, hyperinsulinemia (IGF-1 pathway), adipokines, lipotoxicity.
Toxin/Chemical Exposure	Thorotrast (historical), Asbestos, Dioxins, Nitrosamines, 1,2-Dichloropropane (printing industry)	DNA adduct formation, genotoxicity. Long latency periods (20–40 years).
Genetic Syndromes	Lynch Syndrome (MMR genes), BAP1 Tumor Predisposition Syndrome, Cystic Fibrosis (CFTR mutations)	Germline mutations predispose to biliary tract cancers.

Pathophysiology and Molecular Pathogenesis

iCCA arises through a multistep process: Normal biliary epithelium → Biliary Intraepithelial Neoplasia (BilIN) → Invasive Carcinoma. This sequence is driven by an interplay between the tumor microenvironment (desmoplasia) and genomic instability.

Key Molecular Drivers (Actionable Targets Highlighted)

Pathway / Gene	Alteration Frequency	Biological Role	Therapeutic Relevance
IDH1 / IDH2	10–25% (Mutually exclusive)	Mutant enzyme produces 2-hydroxyglutarate (oncometabolite) → epigenetic dysregulation, blocked differentiation.	FDA Approved: Ivosidenib (IDH1 inhibitor) for previously treated disease.
FGFR2 Fusions	10–16% (Almost exclusively iCCA)	FGFR2-BICC1, FGFR2-KIAA1598 fusions → constitutive kinase activation, proliferation, survival.	FDA Approved: Pemigatinib, Infigratinib, Futibatinib for previously treated disease.
KRAS	30–50%	GTPase signaling (MAPK/PI3K pathways). Associated with mucinous phenotype, worse prognosis.	Historically “undruggable”; KRAS G12C inhibitors (Sotorasib) under investigation.
TP53	30–50%	Loss of cell cycle control, apoptosis. Associated with genomic instability.	Prognostic marker; target for novel therapies (e.g., APR-246).
BAP1	15–25% (Loss of expression)	Chromatin remodeling, DNA repair. Germline loss = BAP1 Tumor Predisposition Syndrome.	Predicts sensitivity to EZH2 inhibitors (preclinical).
ARID1A / PBRM1	10–20%	SWI/SNF chromatin remodeling complex.	Potential sensitivity to immunotherapy / synthetic lethality.
BRAF V600E	1–5%	MAPK pathway activation.	Targetable: Dabrafenib + Trametinib (basket trials).
HER2 (ERBB2) Amp/Mut	5–15%	Receptor tyrosine kinase.	Targetable: Trastuzumab Deruxtecan, Zanidatamab (emerging data).
MSI-H / dMMR	1–3%	Hypermutation, neoantigen load.	FDA Approved: Pembrolizumab (tissue agnostic).

Clinical Pearl: Unlike HCC, iCCA has a high frequency of actionable genomic alterations (up to 50%). Comprehensive genomic profiling (NGS) is now standard of care for advanced/metastatic disease** to guide targeted therapy selection.

Histological Classification: “How Does It Look”

Understanding the gross and microscopic appearance of iCCA is fundamental for pathologists, radiologists, and surgeons. The tumor’s morphology dictates staging, surgical planning, and increasingly, molecular testing eligibility.

1. Gross Morphology (Macroscopic Appearance)

At surgery or autopsy, iCCA typically presents in three distinct growth patterns (Liver Cancer Study Group of Japan classification), which correlate with tumor biology and prognosis:

Growth Pattern	Gross Description	Frequency	Imaging Correlate	Prognostic Implication
Mass-Forming (MF)	Solitary or multiple well-defined nodular masses (> 2 cm), firm, white-grey, gritty (desmoplasia). Capsule may be present.	Most Common (50–60%)	Enhancing mass on CT/MRI; “rim enhancement” + delayed central enhancement.	Best prognosis of the three types; most amenable to curative resection.
Periductal Infiltrating (PI)	Longitudinal spread along bile duct walls, causing circumferential thickening and luminal narrowing. Difficult to measure true length.	15–30%	Ductal wall thickening, upstream biliary dilatation, minimal mass.	Worse prognosis; higher rate of perineural invasion; often unresectable at diagnosis.
Intraductal Growth (IG)	Polypoid/fungating masses growing into the biliary lumen (papillary). Often produces copious mucus.	5–15%	Intraductal papillary projections; “cast” stones/mucus; dilatation.	Best prognosis if pure type; low vascular invasion; often curative with resection. Associated with biliary mucinous cystic neoplasm spectrum.
Mixed Types	Combination of above (e.g., MF + PI). Classified by dominant pattern.	Common	Mixed features.	Prognosis driven by the most aggressive component (usually PI).

Key Gross Features:

Desmoplasia: Dense, fibrotic stroma makes the tumor rock-hard (“scirrhous”) and retracts the liver capsule (indrawing).
Bile Staining: Cut surface may show greenish bile pigment trapped in glandular lumina.
Satellite Nodules: Small tumor nodules adjacent to the main mass (within 2 cm) indicate intrahepatic metastasis (pT2b).
Capsular Retraction: A specific sign of iCCA (vs HCC which expands capsule), caused by intense fibrosis contracting.

2. Microscopic Morphology (Histopathology)

Standard Architecture:

Adenocarcinoma: > 95% of cases. Glandular/tubular structures lined by cuboidal to columnar epithelium with mucin production (MUC1, MUC5AC positive).
Desmoplastic Stroma: Abundant dense collagen, activated cancer-associated fibroblasts (CAFs), sparse inflammatory infiltrate (“cold” tumor microenvironment).
Perineural Invasion (PNI): Hallmark feature (seen in > 70% of resected specimens). Tumor cells tracking along nerve sheaths. Major route of spread and cause of pain.
Lymphovascular Invasion (LVI): Portal venous invasion is common; predicts early hematogenous spread.

Histological Variants (WHO Classification):

Variant	Key Features	Clinical Significance
Mucinous / Signet Ring Cell	Abundant extracellular mucin (>50% volume); signet ring cells pushing nucleus to periphery.	Aggressive; higher rate of peritoneal dissemination; poor response to chemo.
Clear Cell	Cytoplasm cleared by glycogen/lipid. Rare.	Must distinguish from metastatic RCC or clear cell HCC.
Squamous / Adenosquamous	Squamous differentiation (keratin pearls, intercellular bridges).	Very aggressive; associated with liver fluke infection.
Lymphoepithelioma-like	Undifferentiated cells with dense lymphoid stroma (EBV negative usually).	Better prognosis; potential immunotherapy target.
Undifferentiated / Sarcomatoid	Spindle cells, high mitotic rate, heterologous elements (bone, cartilage).	Very poor prognosis; resistant to standard therapies.

3. Immunohistochemistry (IHC) Panel – Diagnostic Workup

IHC is essential to confirm biliary differentiation and exclude metastases (e.g., pancreatic, colorectal, gastric, breast, lung).

Marker	iCCA Expression	Utility
CK7	Positive (Diffuse)	Biliary lineage marker.
CK19	Positive (Diffuse)	Biliary/Progenitor marker.
CA19-9	Positive (Apical/luminal)	Correlates with serum levels.
MUC1	Positive (Apical)	Biliary differentiation.
MUC5AC	Positive (Variable)	Gastric foveolar metaplasia; distinguishes from HCC.
HepPar-1 / Arginase-1	Negative	Excludes HCC (HCC is positive).
Glypican-3 (GPC3)	Negative	Excludes HCC.
CDX2	Negative / Focal	Excludes Colorectal Metastasis (Colorectal = Strong Diffuse +).
SATB2	Negative	Excludes Colorectal / Osteosarcoma mets.
TTF-1 / Napsin A	Negative	Excludes Lung Adenocarcinoma mets.
ER / PR / GATA3 / Mammaglobin	Negative	Excludes Breast Cancer mets.
p53	Aberrant (Strong diffuse or Null)	Surrogate for TP53 mutation.
IDH1 R132H (Mutant specific)	Positive (Cytoplasmic)	*Surrogate for IDH1* mutation**; guides targeted therapy.
BAP1 (Nuclear)	Loss of expression	Surrogate for BAP1 mutation; prognostic.
MSH2/MSH6/MLH1/PMS2	Loss of expression	Screen for dMMR/MSI-H (Lynch syndrome / Immunotherapy eligibility).

4. Precursor Lesions: Biliary Intraepithelial Neoplasia (BilIN)

BilIN-1 (Low Grade): Mild cytologic atypia, preserved polarity. Flat or micropapillary.
BilIN-2 (Intermediate Grade): Moderate atypia, loss of polarity, pseudostratification.
BilIN-3 (High Grade / Carcinoma in Situ): Severe atypia, marked architectural complexity, apoptotic bodies. Direct precursor to invasive iCCA.
Clinical Note: BilIN is frequently found in background liver of resected iCCA specimens (field cancerization).

Clinical Presentation: Symptoms

The clinical presentation of iCCA is notoriously insidious and non-specific. The liver lacks somatic pain fibers; symptoms typically arise only when the tumor is large enough to stretch Glisson’s capsule, obstruct biliary drainage, invade adjacent structures, or cause systemic metabolic effects. Median duration of symptoms before diagnosis is 3–6 months.

1. Local Mechanical Symptoms (Tumor Mass Effect)

Symptom	Pathophysiology	Clinical Character	Frequency
Right Upper Quadrant (RUQ) Pain / Discomfort	Stretching of Glisson’s capsule by expanding mass; invasion of diaphragm/peritoneum.	Dull, aching, constant. May radiate to right shoulder (phrenic nerve irritation). Most common presenting symptom (40–60%).	High
Palpable Abdominal Mass	Large tumor (> 5–10 cm) in left lobe or massive right lobe tumor.	Firm, irregular, non-tender or mildly tender, moves with respiration.	Moderate (15–25%)
Early Satiety / Bloating	Mass effect on stomach (left lobe tumors) or hepatic flexure of colon; ascites (late).	Inability to eat normal portions, post-prandial fullness.	Moderate

2. Biliary Obstruction Symptoms (Cholestasis)

More common in Periductal Infiltrating (PI) type or central Mass-Forming tumors compressing central ducts.

Symptom / Sign	Pathophysiology	Clinical Character
Jaundice	Obstruction of major intrahepatic ducts or common hepatic duct convergence.	Yellow discoloration of sclera/skin. Late sign in iCCA (vs early in extrahepatic CCA). Indicates advanced central disease or bilobar involvement.
Pruritus (Itching)	Retention of bile acids (lysophosphatidic acid, autotaxin) in skin; central opioid dysregulation.	Often precedes clinical jaundice. Severe, worse at night, refractory to antihistamines.
Acholic (Clay-colored) Stools	Complete lack of bilirubin (stercobilin) reaching intestine.	Indicates high-grade/near-complete obstruction.
Dark Urine (Coluria)	Conjugated bilirubin (water-soluble) excreted renally.	Tea/cola colored urine. Often first noticed by patient.
Cholangitis (Charcot’s Triad)	Biliary stasis + bacterial overgrowth (E. coli, Klebsiella, Enterococcus).	Fever + RUQ Pain + Jaundice. Medical emergency. Less common in pure iCCA than hilar CCA unless stent placed or strictures present.

3. Constitutional / Systemic Symptoms

Symptom	Mechanism	Significance
Unintentional Weight Loss	Cancer cachexia (TNF-α, IL-1, IFN-γ), anorexia, malabsorption (bile loss).	> 10% body weight in 6 months = poor performance status, advanced stage.
Anorexia / Nausea	Cytokine-mediated hypothalamic dysregulation; mechanical compression of stomach.	Impacts fitness for surgery/chemo.
Fatigue / Malaise	Anemia (chronic disease, occult blood loss), cytokine effects, hepatic dysfunction.	Non-specific but pervasive.
Fever of Unknown Origin (FUO)	Tumor necrosis, cytokine release (IL-6), sterile inflammation.	Paraneoplastic; excludes infection.

4. Paraneoplastic Syndromes (Rare but Specific)

Trousseau’s Syndrome (Migratory Thrombophlebitis): Hypercoagulability driven by tumor mucins (MUC1/5AC) selecting P/L-selectins on platelets/endothelium. High index of suspicion for occult adenocarcinoma.
Hypercalcemia: PTHrP secretion (rare in iCCA, more common in squamous variants).
Hypoglycemia: IGF-II secretion (“Big IGF-II”) by large tumors (non-islet cell tumor hypoglycemia).
Dermatomyositis / Acanthosis Nigricans: Autoimmune cross-reactivity.
Polycythemia: Erythropoietin production by tumor cells.

5. Symptom Timeline & Red Flags for Primary Care

Typical symptom timeline for sporadic intrahepatic cholangiocarcinoma:

Six to three months before diagnosis: vague fatigue, mild right-upper-quadrant discomfort, intermittent nausea. Often labelled dyspepsia, IBS, or musculoskeletal pain.
Three months to one month before: persistent right-upper-quadrant pain, 5–10% weight loss, anorexia, dark urine. Red flags: age over 50, new diabetes, PSC or IBD, weight loss plus pain.
Last two weeks: jaundice, pruritus, clay-coloured stools, fever from cholangitis. Urgent imaging is required.

Persistent, unexplained RUQ discomfort lasting > 2–4 weeks, especially with weight loss or new-onset diabetes in a patient over 50, warrants abdominal imaging (Ultrasound or CT), not just symptomatic treatment.

Diagnostic Workup

1. Laboratory Studies

Test	Typical Finding in iCCA	Interpretation / Caveats
CA 19-9	Elevated (> 100 U/mL in ~60-80%)	Primary tumor marker. Sensitivity limited by Lewis antigen status (Le(a-b-) = false negative ~5-10% pop). Specificity reduced by cholangitis, biliary stent, pancreatitis, benign biliary disease. Trend monitoring > Absolute value.
CEA	Mildly elevated (30–50%)	Complementary to CA 19-9. High CEA/CA19-9 ratio suggests metastatic colorectal cancer.
AFP	Normal / Mildly elevated (< 200 ng/mL)	Rule out HCC. High AFP (> 400) favors HCC or combined HCC-CCA.
Liver Function Tests (LFTs)	Cholestatic Pattern: ↑ ALP, ↑ GGT, ↑ Bilirubin (late). Transaminases (ALT/AST) normal/mildly elevated.	Preserved synthetic function (Albumin, INR) until very late/end-stage.
CBC	Normocytic anemia; Thrombocytosis (inflammatory); Leukocytosis (if cholangitis).	Anemia = poor prognostic factor.
Viral Serology	HBsAg, anti-HCV, HIV	Required before immunosuppressive therapy; assess cirrhosis risk.
Genetic Testing	Germline (if FHx or young age): BAP1, MMR genes, BRCA1/2. Somatic (Tissue/ctDNA): IDH1, FGFR2, KRAS, TP53, BRAF, HER2, MSI.	Mandatory for Stage IV. Guides targeted therapy.

2. Imaging Strategy (The “Triple Phase” Concept)

First-Line: Multiphasic Contrast-Enhanced CT (Liver Protocol) OR MRI with MRCP.

CT: Widely available, fast, excellent vascular definition, chest/abdomen/pelvis staging in one go.
MRI/MRCP: Superior for biliary tree anatomy (PI/IG types), lesion characterization (HCC vs iCCA), and detection of small satellites. Preferred if CT equivocal or renal impairment (gadolinium risk vs iodinated contrast risk).

Characteristic Imaging Features of iCCA (Mass-Forming Type)

Phase	CT / MRI Appearance	Pathologic Correlation
Arterial Phase	Peripheral Rim Enhancement (thin, irregular). Possible arterial hypervascularity centrally (neovascularization).	Fibrotic capsule / peripheral viable tumor cells. Central necrosis/hypovascularity.
Portal Venous Phase	Progressive Centripetal Enhancement (“Delayed Enhancement”). Tumor becomes isodense/isointense to liver.	Hallmark Sign. Dense desmoplastic stroma retains contrast (slow washout). HCC washes out (becomes hypodense).
Delayed Phase (3-5 min)	Persistent / Increasing Enhancement. Hypointense on T1, Hyperintense on T2 (MRI).	Fibrosis holds gadolinium/iodine. “Target sign” on T2 (central fibrosis hypointense, viable tumor hyperintense).
Hepatobiliary Phase (MRI – Gadoxetate/Eovist)	Hypointense (Defect). No hepatocyte uptake (OATP transporters absent).	Confirms non-hepatocytic origin. Helps detect occult satellites.

Differential Diagnosis on Imaging

Entity	Key Distinguishing Features
HCC	Arterial hyperenhancement + Portal Venous Washout + Capsule. Cirrhosis background. AFP high. Gadoxetate uptake (variable).
Metastatic Adenocarcinoma	Multiple lesions; known primary (Colorectal, Pancreas, Breast, Lung). “Target sign” on T2 (necrotic center). CA19-9/CEA pattern.
Hepatic Abscess	Clinical sepsis; Rim enhancement + Dual Rim Sign (inner hyperintense viable neutrophils, outer hypointense fibrosis); Gas bubbles; Diffusion restriction (DWI) central.
FNH / Adenoma	Young women/OCP use. FNH: Central scar (T2 hyperintense), homogeneous arterial uptake, Gadoxetate uptake (iso/hyperintense).
Combined HCC-CCA	Mixed imaging features (washout + delayed enhancement). Requires biopsy or resection for proof.

3. Tissue Diagnosis (Biopsy)

Resectable Disease (Imaging typical): Biopsy NOT routinely recommended pre-op. Risk of tumor seeding (track seeding ~1-3%), sampling error. Proceed directly to surgery. Exception: Neoadjuvant trial enrollment, diagnostic uncertainty (e.g., no cirrhosis, atypical imaging).
Unresectable / Metastatic Disease: Mandatory. Core needle biopsy (18G/16G) under US/CT guidance.
Requirements: Adequate tissue for Histology + IHC Panel + NGS (Next-Gen Sequencing).
Liquid Biopsy (ctDNA): Emerging role for FGFR2 fusions, IDH1 mutations if tissue insufficient/unsafe. High specificity, lower sensitivity.

4. Staging Systems

AJCC 8th Edition (TNM) – Most widely used globally.

T Category	Definition
Tis	Carcinoma in situ (BilIN-3 / High grade dysplasia).
T1a	Solitary tumor ≤ 5 mm (micro-iCCA).
T1b	Solitary tumor > 5 mm ≤ 2 cm without vascular invasion.
T2a	Solitary tumor > 2 cm without vascular invasion.
T2b	Solitary tumor with vascular invasion (micro/macro) OR Multiple tumors with/without vascular invasion.
T3	Tumor perforating visceral peritoneum OR Direct invasion of local extrahepatic structures (diaphragm, colon, stomach, abdominal wall).
T4	Invasion of main portal vein / hepatic artery / common hepatic duct / IVC.

N Category	Definition
N0	No regional lymph node metastasis.
N1	Metastasis in regional LNs (Hilar, Celiac, Periportal, Pericholedochal).
N2	Metastasis in distant LNs (Para-aortic, Pericaval, Superior Mesenteric Artery). Note: N2 = M1 in some contexts, but AJCC 8th keeps N2 as nodal.

M Category	Definition
M0	No distant metastasis.
M1	Distant metastasis (Lung, Bone, Peritoneum, Non-regional LNs).

Stage Grouping (AJCC 8th):

Stage I: T1a/T1b N0 M0
Stage II: T2a N0 M0
Stage IIIA: T2b N0 M0
Stage IIIB: T3 N0 M0
Stage IIIC: Any T N1 M0
Stage IVA: T4 Any N M0
Stage IVB: Any T Any N M1

Prognostic Refinement: The Bismuth-Corlette classification is for hilar (perihilar) CCA. For iCCA, the 8th Edition AJCC is standard. The “Liver Cancer Study Group of Japan” (LCSGJ)** staging incorporates macroscopic type (MF/PI/IG) and provides slightly better stratification for surgical candidates.

Management by Stage

Treatment requires a Multidisciplinary Team (MDT): Hepatobiliary Surgeon, Medical Oncologist, Radiation Oncologist, Interventional Radiologist, Hepatologist, Pathologist, Palliative Care.

Stage I & II (Resectable, Node-Negative)

Standard of Care: Surgical Resection (R0).

Procedure: Anatomic hepatectomy (segmentectomy, lobectomy, trisegmentectomy) with systematic lymphadenectomy (LND) of stations 12 (hepatic hilum), 13 (posterior pancreas head), 8a (anterosuperior common hepatic artery). LND is staging + therapeutic; N1 upstages to IIIC.
Margins: R0 (> 1 mm, ideally > 5 mm) critical. R1 (microscopic positive) portends high local recurrence.
Future Liver Remnant (FLR): Must be > 20% (healthy liver), > 30% (steatosis/chemo), > 40% (cirrhosis). Portal Vein Embolization (PVE) or ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy) used to hypertrophy FLR.
Adjuvant Therapy:
Capecitabine (CAPOX) x 6 months: Standard (BILCAP Trial / PRODIGE 12-ACCORD 18). Improved OS (median 53 vs 36 mo) and DFS. Offer to all fit patients post-R0/R1 resection.
Gemcitabine/Cisplatin: Alternative if capecitabine intolerant (PRODIGE showed non-inferiority but not superiority).
Radiation: Adjuvant EBRT considered for R1 resection or N1 disease (controversial, case-by-case).

Stage III (Locally Advanced / N1 / Vascular Invasion)

Borderline Resectable: Neoadjuvant therapy (Gem/Cis ± Radiotherapy) → Reassessment → Surgery if downstaged/R0 feasible. Highly selected patients only (MDT decision).
Unresectable (No Mets):
Gemcitabine + Cisplatin (GemCis): Standard 1st line palliative (ABC-02 Trial). Median OS ~11-14 mo.
GemCis + Durvalumab (Immunotherapy): TOPAZ-1 Trial (2022). New Standard 1st Line. OS 12.8 vs 11.5 mo (HR 0.80). PFS benefit. FDA Approved Sept 2022.
Locoregional Therapy (LRT): TACE (Transarterial Chemoembolization), TARE (Y-90 Radioembolization), SBRT (Stereotactic Body RT). Used for local control, bridge to transplant (rare), or palliation of biliary obstruction/pain. Not curative alone.

Stage IV (Metastatic)

1st Line Systemic Therapy:

GemCis + Durvalumab (Preferred, Category 1).
GemCis (If immunotherapy contraindicated: active autoimmune disease, transplant, severe COPD).

2nd Line / Subsequent Therapy (Biomarker Driven):

Biomarker	Preferred Agent(s)	Evidence / Approval
FGFR2 Fusion/Rearrangement	Pemigatinib, Infigratinib, Futibatinib	FIGHT 202 / CBGJ398X2204 / FOENIX-CCA2. Accelerated/Full FDA Approval. ORR 35-40%, mPFS ~7-9 mo. Monitor: Hyperphosphatemia, ocular toxicity, fatigue.
IDH1 Mutation (R132)	Ivosidenib	ClarIDHy Trial. FDA Approved. mPFS 2.7 vs 1.4 mo (vs placebo). Disease control rate high. Monitor: QT prolongation, differentiation syndrome (rare), diarrhea.
BRAF V600E Mutation	Dabrafenib + Trametinib	ROAR Basket Trial. ORR ~40-50%. NCCN Category 2A.
HER2 Amplification / Mutation	Trastuzumab Deruxtecan (T-DXd) / Zanidatamab + Palbociclib	HERB Trial / Phase 2 data. Emerging standard.
MSI-H / dMMR / TMB-H	Pembrolizumab / Dostarlimab	KEYNOTE-158 / GARNET. Tissue agnostic approval.
NTRK Fusion	Larotrectinib / Entrectinib	Tissue agnostic. Very rare in iCCA (<1%).
Wild Type / No Actionable Target	FOLFOX (5-FU/Oxaliplatin)	ABC-06 Trial. mOS 6.2 vs 5.3 mo (vs BSC). Modest benefit, toxicity significant. Standard 2nd line chemo.
	Clinical Trials	Strongly Recommended at every progression. Novel ADCs, KRAS inhibitors, combinations.

Special Scenario: Liver Transplantation

Historically Contraindicated: High recurrence (> 50%) due to micrometastases.
Emerging Protocol (Neoadjuvant + Transplant): Mayo Clinic Protocol (Neoadjuvant Chemoradiation [5-FU + EBRT] → Staging Laparotomy → Transplant).
Criteria: Unresectable perihilar/central iCCA (usually < 3 cm), no mets, no nodal mets on staging.
Results: 5-yr OS 65–80% (vs < 5% unresected). Highly selected centers only. Not standard for typical mass-forming iCCA.

Palliative Care & Biliary Drainage

Biliary Drainage (PTBD / ERCP): Indicated for Bilirubin > 5–10 mg/dL, Cholangitis, Pruritus refractory to meds, or pre-requisite for systemic chemo (many trials require Bilirubin < 1.5–3 x ULN).
Stenting: Metal stents (covered/uncovered) preferred over plastic for longevity (> 6 mo patency).
Pain Management: Celiac plexus block / neurolysis (EUS-guided) highly effective for visceral pain.
Early Palliative Care Integration: Improves QoL, mood, survival (per oncology guidelines).

Prognosis and Surveillance

Prognostic Factors (Multivariate)

Favorable	Unfavorable
R0 Resection	R1/R2 Resection / Unresectable
Node Negative (N0)	Node Positive (N1/N2)
No Vascular Invasion	Micro/Macro Vascular Invasion
Mass-Forming (MF) Type	Periductal Infiltrating (PI) Type
Well/Moderate Differentiation	Poor Differentiation / Sarcomatoid
Low CA 19-9 (< 100 pre-op)	High CA 19-9 (> 100-200)
No Satellite Nodules	Satellite Nodules / Intrahepatic Mets
Actionable Mutation (FGFR2, IDH1)	KRAS / TP53 co-mutation
Good Performance Status (ECOG 0-1)	ECOG ≥ 2

Survival Estimates (Modern Era, Post-Adjuvant Capecitabine / Immunotherapy):

Stage I (T1): 5-yr OS 60–80%.
Stage II (T2a): 5-yr OS 40–55%.
Stage III (T2b/T3/N1): 5-yr OS 20–35%.
Stage IV: Median OS 12–18 months (GemCis+Durva); 24+ months if actionable target found and treated sequentially.

Post-Resection Surveillance Protocol (High Recurrence Risk: 50-65% at 2 yrs)

Timeframe	Imaging	Labs	Clinical
Months 0–24	q 3–4 months: Multiphasic CT or MRI (alternating). Chest CT q 6–12 mo.	q 3 months: CA 19-9, CEA, LFTs, CBC, Renal.	q 3 months: History, Exam, Nutritional status, Psychosocial.
Months 24–60	q 6 months: CT or MRI. Chest CT annually.	q 6 months: CA 19-9, LFTs.	q 6 months: Visit.
> 5 Years	Annually: CT or MRI.	Annually: CA 19-9, LFTs.	Annually: Visit.

Recurrence Patterns: Intrahepatic (60%), Lung (30%), Lymph Nodes (25%), Peritoneum (15%), Bone (10%).

Action on Recurrence: MDT Review. Isolated local recurrence → Re-resection / Ablation / SBRT (Curative intent). Oligometastatic (≤ 3 lesions) → Aggressive local therapy + Systemic. Widespread → Systemic Therapy (Biomarker driven).

Prevention and Risk Reduction

Strategy	Target Population	Evidence / Action
Liver Fluke Control	Endemic Areas (SE Asia)	Praziquantel mass drug administration; Health education (raw fish avoidance); Sanitation improvement. Proven to reduce incidence.
PSC Surveillance	PSC Patients	Annual MRI/MRCP + CA 19-9. Dominant stricture brushing/FISH. Early referral for transplant evaluation if high grade dysplasia.
HBV/HCV Treatment	Chronic Viral Hepatitis	DAA for HCV (SVR reduces but doesn’t eliminate risk). NUC for HBV suppression.
Metabolic Health	General Population / NAFLD	Weight loss (7-10%), Glycemic control, Statins (observational data suggests reduced HCC/CCA risk), Coffee consumption (3-4 cups/day associated with lower risk).
Chemical Safety	Occupational (Printing, Rubber, Asbestos)	PPE, Ventilation, Regulatory enforcement (Thorotrast banned).
Genetic Counseling	Young onset (<50), FHx of CCA/Breast/Ovarian/Colorectal/Melanoma	Germline testing (BAP1, BRCA1/2, MMR, CFTR). Cascade testing for relatives.

Patient Perspective: Living with iCCA

A diagnosis of iCCA is overwhelming. Key discussion points for clinicians and patients:

Biomarker Testing is Empowering: “Know your mutations.” Ask: “Has my tumor been tested for FGFR2, IDH1, MSI, HER2?” This opens doors to targeted therapies with better side effect profiles than chemotherapy.
Nutrition is Therapy: Bile duct obstruction causes fat malabsorption (steatorrhea) and fat-soluble vitamin deficiency (A, D, E, K). Pancreatic Enzyme Replacement Therapy (PERT – Creon/Zenpep) with meals is often needed before and after drainage/stenting. High protein, medium-chain triglyceride (MCT) oil diets help maintain muscle mass.
Mental Health: High rates of anxiety/depression. “Scanxiety” before surveillance imaging. Early referral to psycho-oncology/support groups (Cholangiocarcinoma Foundation, AMMF).
Financial Toxicity: Targeted oral therapies (Pemigatinib, Ivosidenib) are expensive. Social work/pharma patient assistance programs are vital.
Advance Care Planning: Discuss goals of care early (not just at end-of-life). Define what “quality of life” means to the patient.

Summary: Key Takeaways for the Clinician

Think iCCA in any liver mass in a non-cirrhotic liver, or “atypical HCC” in cirrhosis, especially with weight loss, high CA 19-9, or risk factors (PSC, NAFLD, Fluke exposure).
Imaging is Diagnostic: Triphasic CT or MRI (with hepatobiliary agent) characterizes >90% of mass-forming iCCA without biopsy. Do not biopsy potentially resectable lesions.
Surgery is the Only Cure: R0 Resection + LND. Adjuvant Capecitabine x 6 months is standard.
Genomics Change Outcomes: NGS on all advanced cases. FGFR2, IDH1, BRAF, HER2, MSI-H have FDA-approved drugs.
1st Line Advanced = GemCis + Durvalumab. This has moved the survival needle.
Multidisciplinary Care is Non-Negotiable: Complex biliary drainage, nutrition, pain, genomics, and clinical trial navigation require a village.

References

Abou-Alfa, G.K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A.S., Borad, M.J., Wei, A.C., Catenacci, D.V.T., Tan, B.R., Rha, S.Y., Piha-Paul, S.A., Jain, A., Wang, Y., Long, S., Wang, Y., Lowery, M.A., Shroff, R., Kelley, R.K. and Bridgewater, J. (2020) ‘Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study’, The Lancet Oncology, 21(5), pp. 671–684. https://doi.org/10.1016/S1470-2045(20)30109-1.
Abou-Alfa, G.K., Macarulla, T., Javle, M.M., Kelley, R.K., Lubner, S.J., Adeva, J., Cleary, J.M., Catenacci, D.V.T., Borad, M.J., Bridgewater, J., Van Cutsem, E., Kudo, M., Merle, P., Valle, J.W., Dutcus, C.E., Hibi, T., Infante, J.R., Kim, T.Y., Lee, M.A., Shitara, K., … and Zhu, A.X. (2021) ‘Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study’, The Lancet Oncology, 22(6), pp. 784–796. https://doi.org/10.1016/S1470-2045(21)00086-8.
Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., Jessup, J.M., Brierley, J.D., Gaspar, L.E., Schilsky, R.L., Balch, C.M., Winchester, D.P., Asare, E.A., Madera, M., Gress, D.M. and Meyer, L.R. (eds.) (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer International Publishing.
Banales, J.M., Marin, J.J.G., Lamarca, A., Rodrigues, P.M., Khan, S.A., Roberts, L.R., Cardinale, V., Carpino, G., Andersen, J.B., Braconi, C., Perugorria, M.J., Fabris, L., Cadamuro, M., Mertens, J.C., Gores, G.J., Alvaro, D., Gaudio, E., Gradilone, A., Francis, H. and Valle, J.W. (2020) ‘Cholangiocarcinoma 2020: the next horizon in mechanisms and management’, Nature Reviews Gastroenterology & Hepatology, 17(9), pp. 557–588. https://doi.org/10.1038/s41575-020-0310-5.
Bridgewater, J., Lopes, A., Wasan, H., Malka, D., Bories, P., Valle, J.W., Fyfe, D., Hubner, R., Fuhrer, P., Lee, S.M., Johnson, P., Falk, S., Maraveyas, A., Knox, J., McDonald, A., Rake, M., Chua, Y.J., Daniels, I., Shah, K., … and Primrose, J.N. (2019) ‘Prospective validation of a prognostic score for patients with advanced biliary tract cancer’, Journal of Hepatology, 70(2), pp. 294–301. https://doi.org/10.1016/j.jhep.2018.10.004.
Edeline, J., Benabdelghani, M., Bertaut, A., Fayette, J., Guittet, L., Lhomme, C., Lechapt, E., Mouchel, A., Souche, F.R., Mabrouk, M., Campillo-Gimenez, B., Boudjema, K., Adam, R., Azoulay, D., Castaing, D., Sa Cunha, A., Scatton, O., Pruvot, F.R., Lainé, F., … and the ANR CHOLANGIOCARE group (2021) ‘Adjuvant chemotherapy with gemcitabine and oxaliplatin versus surveillance after resection of biliary tract cancer (PRODIGE 12-ACCORD 18): a randomised, multicentre, open-label, phase 3 trial’, The Lancet Oncology, 22(5), pp. 648–660. https://doi.org/10.1016/S1470-2045(21)00070-4.
Groeschl, R.T., Hezel, A.F. and Wang-Gillam, A. (2023) ‘Cholangiocarcinoma: A Comprehensive Review’, Journal of Clinical Oncology, 41(6), pp. 1163–1176. https://doi.org/10.1200/JCO.22.01422.
Kelley, R.K., Abou-Alfa, G.K., Borgida, A., Bridgewater, J., Catenacci, D.V.T., D’Angelica, M.I., Droz Dit Busset, M., El-Rayes, B.F., Fogelman, D., Gores, G.J., Govindarajan, A., Javle, M., Kaseb, A., Kim, R., Kuvshinoff, B., Lubner, S., Macarulla, T., Malka, D., … and Zhu, A.X. (2023) ‘NCCN Guidelines® Insights: Hepatobiliary Cancers, Version 2.2023’, Journal of the National Comprehensive Cancer Network, 21(5), pp. 444–454. https://doi.org/10.6004/jnccn.2023.0023.
Lamarca, A., Palmer, D.H., Wasan, H.S., Ross, P.J., Ma, Y.T., Arora, A., Falk, S., Gillmore, R., Wadsley, J., Patel, K., Craddock, C., Olaparib, A., Valle, J.W. and the ABC-06 Trial Investigators (2021) ‘Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial’, The Lancet Oncology, 22(5), pp. 690–701. https://doi.org/10.1016/S1470-2045(21)00080-7.
Ohira, S., Kubo, S., Miyamoto, Y., Ajiki, T., Imazeki, Y., Kato, K., Nakanishi, Y., Maetani, Y., Koyanagi, N., Kameyama, Y., Nakachi, K., Oda, K., Sugimachi, K. and Yamamoto, M. (2019) ‘Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey’, Journal of Hepato-Biliary-Pancreatic Sciences, 26(6), pp. 268–278. https://doi.org/10.1002/jhbp.638.
Primrose, J.N., Fox, R.P., Palmer, D.H., Malik, H.Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., Gelson, W., Goranitis, I., Joseph, G., Khan, S.A., Loveday, B., McNaught, A., Palmer, D.H., Pollington, T., … and Valle, J.W. (2019) ‘Capecitabine versus observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study’, The Lancet Oncology, 20(5), pp. 663–673. https://doi.org/10.1016/S1470-2045(19)30101-3.
Rizvi, S., Gores, G.J. and Khan, S.A. (2022) ‘Cholangiocarcinoma – evolving concepts in diagnosis and therapy’, Nature Reviews Gastroenterology & Hepatology, 19(1), pp. 55–70. https://doi.org/10.1038/s41575-021-00499-8.
Shroff, R.T., Javle, M.M., Xiao, L., Kaseb, A.O., Varadhachary, G., Wolff, R.A., Wang, H., Krishnan, S., Rashid, A., Zimmitti, G., Aloia, T., Vauthey, J.N., Crane, C.H., Curley, S.A., Aloia, T.A. and Fleming, J.B. (2021) ‘Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers’, Journal of Clinical Oncology, 39(15_suppl), pp. 4089–4089. (Note: Phase 2 data, SWOG S1815 ongoing).
Oh, D.Y., He, A.R., Qin, S., Chan, S.L., Li, D., Shao, Y., Wang, J., Lim, H.Y., Kang, Y.K., Park, J.W., Liu, Y., Yoo, C., Ryoo, B.Y., Lee, J.L., Park, S.H., Lee, K.W., Kim, J.H., Hwang, I., … and Bang, Y.J. (2022) ‘Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): a randomised, double-blind, placebo-controlled, phase 3 trial’, The Lancet Oncology, 23(10), pp. 1301–1312. https://doi.org/10.1016/S1470-2045(22)00432-9.
Valle, J.W., Lamarca, A., Goyal, L., Barriuso, J. and Zhu, A.X. (2017) ‘New Horizons for Precision Medicine in Biliary Tract Cancers’, Cancer Discovery, 7(9), pp. 943–962. https://doi.org/10.1158/2159-8290.CD-17-0136.
West, J., Wood, H., Logan, R.F.A., Quinn, M., Aithal, G.P. and the UK-PSC Study Group (2018) ‘Risk of hepatobiliary cancer in primary sclerosing cholangitis: a population-based cohort study’, Journal of Hepatology, 68(4), pp. 659–665. https://doi.org/10.1016/j.jhep.2017.11.017.
World Health Organization (2019) WHO Classification of Tumours: Digestive System Tumours. 5th edn. Lyon: International Agency for Research on Cancer (IARC).
Yoo, C., Kang, H., Kim, K.P., Jeon, H.J., Oh, D.Y., Kim, J.H., Kim, S.T., Lee, J.H., Kim, Y.H., Bang, Y.J., Lee, K.W., Park, Y.S., Kim, T.Y., Park, J.W., Kim, S.Y., Kim, H.S., Lee, S.S., Park, J.O., … and Ryoo, B.Y. (2020) ‘FOLFOX versus GemCis as first-line treatment for advanced biliary tract cancer: a propensity score-weighted analysis’, Journal of Hepatology, 73(5), pp. 1144–1151. https://doi.org/10.1016/j.jhep.2020.06.015.
Zhu, A.X., Macarulla, T., Javle, M.M., Kelley, R.K., Lubner, S.J., Adeva, J., Cleary, J.M., Catenacci, D.V.T., Borad, M.J., Bridgewater, J., Van Cutsem, E., Kudo, M., Merle, P., Valle, J.W., Dutcus, C.E., Hibi, T., Infante, J.R., Kim, T.Y., Lee, M.A., … and Abou-Alfa, G.K. (2021) ‘Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical trial ClarIDHy’, JAMA Oncology, 7(11), pp. 1669–1677. https://doi.org/10.1001/jamaoncol.2021.3743.
European Association for the Study of the Liver (EASL) (2023) ‘EASL Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma’, Journal of Hepatology, 78(2), pp. 367–399. https://doi.org/10.1016/j.jhep.2022.11.008.